Aligos Therapeutics, Inc. — FY 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. Although the request refers to 2022 Q4, this is an annual filing; the financial figures below are for the full year, not the fourth quarter alone.
Business context
Aligos is a clinical-stage biopharmaceutical company developing therapies for liver diseases and viral infections. It has no approved products and has never generated product-sales revenue. Its reported collaboration revenue is not product revenue. In February 2023, after year-end, the company reprioritized its portfolio toward clinical NASH and COVID-19 programs while planning to complete specified ongoing CHB cohorts.
Financial performance and liquidity
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Collaboration revenue | $13.9 million | $4.4 million |
| Research and development expense | $85.1 million | $104.2 million |
| General and administrative expense | $26.4 million | $28.5 million |
| Operating loss | $97.6 million | $128.3 million |
| Net loss | $96.0 million | $128.3 million |
| Net loss per share, basic and diluted | $2.25 | $3.22 |
| Cash used in operating activities | $79.4 million | $115.7 million |
- Collaboration revenue rose $9.5 million, primarily reflecting recognition of Merck upfront payments as research work progressed. No collaboration milestone revenue was recognized in either year.
- R&D expense fell $19.1 million, mainly from lower third-party costs following the discontinuation of STOPS and ASO programs and reduced manufacturing activity; this was partly offset by higher employee and facility costs. Direct CHB program expense declined to $20.7 million from $45.8 million, while coronavirus program expense increased to $5.7 million from $2.1 million.
- The smaller net loss and operating cash use chiefly reflect lower operating expenses. Interest income increased to $1.5 million from $0.2 million.
- At December 31, 2022, cash and cash equivalents were $81.3 million, short-term investments $44.5 million, and restricted cash $0.1 million. Total assets were $146.7 million; total liabilities $42.8 million; and stockholders’ equity $103.9 million. The filing reports no borrowings; liabilities include operating and finance lease obligations.
- There are no product-sales margins to assess. Collaboration revenue is reported against operating expenses, and the company remained substantially loss-making.
- Management stated that cash, cash equivalents and investments were expected to fund operations for at least 12 months following issuance of the financial statements. This estimate depends on development plans and other assumptions and is not a guarantee.
Programs, outlook and material developments
- NASH: ALG-055009, a THR-β agonist, was in Phase 1. Preliminary short-duration data indicated tolerability, dose-proportional pharmacokinetics and expected lipid-related effects. The company planned a Phase 2 proof-of-concept study and anticipated submitting its protocol to the FDA in Q4 2023, subject to completing relative-bioavailability work, toxicology studies and Phase 2 drug supply preparation. NASH oligonucleotide work, including the Merck collaboration, was in preclinical stages.
- COVID-19: ALG-097558, a coronavirus protease inhibitor, had preclinical activity data. The company anticipated a Phase 1 CTA filing and healthy-volunteer dosing in Q2 2023. Its potency and potential to avoid ritonavir boosting are company-reported preclinical comparisons, not clinical findings.
- CHB: ALG-000184 and ALG-125755 were in Phase 1 studies. Preliminary ALG-000184 results reported antiviral-marker reductions in certain cohorts; these were interim data and not evidence of a functional cure. The company planned to continue selected cohorts during 2023. In February 2023, it said it would complete ongoing 48-week CAM-E cohorts and single-ascending-dose siRNA cohorts, rather than maintain CHB as a primary portfolio focus.
- Reprioritization and workforce: The February 2023 portfolio reprioritization emphasized clinical NASH and COVID-19 programs and continued support for collaborations. It included an approximately 10% workforce reduction; the company expected a one-time charge of about $1.0 million in Q1 2023.
- Merck collaboration: Merck gave notice in February 2023 to terminate one collaboration target. The filing describes potential milestone and royalty payments for retained collaboration programs, but these are contingent and not assured revenue.
- Janssen litigation: Janssen alleged that certain former employees assigned inventions to Aligos that Janssen claims to own, seeking, among other relief, intellectual-property assignment and damages. Aligos disputes the allegations and filed counterclaims. The filing does not provide a clear estimate of potential financial exposure; no related contingency liability was accrued at year-end.
Key risks and unusual items
- Continued operating losses, no product revenue, substantial future development costs and reliance on additional financing; the company noted limitations on shelf and ATM issuance under the “baby shelf” rule.
- Clinical and regulatory uncertainty, including safety, efficacy, trial enrollment, manufacturing and approval risks. Aligos had discontinued ALG-010133 for insufficient antiviral activity and ALG-020572 after ALT elevations, including a serious adverse event.
- Dependence on contract research and manufacturing organizations, collaborators and licensors; competition in NASH, COVID-19 and CHB; and uncertainty over intellectual-property scope and enforcement.
- Potential dilution or restrictive terms from future financing, as well as reimbursement, pricing, legal, data-security and operational risks. The company also cited macroeconomic, interest-rate and pandemic-related uncertainty.
- Aligos reported no material non-cancellable purchase commitments and no off-balance-sheet arrangements. Its independent auditor issued an unqualified opinion on the financial statements; the auditor was not engaged to opine on internal-control effectiveness. Management reported effective disclosure controls and internal control over financial reporting as of December 31, 2022.
Most important facts for investors to verify
- Whether the cash runway remains adequate after the February 2023 reprioritization, workforce reduction, continuing clinical costs and any financing activity after the filing.
- Actual clinical and regulatory progress for ALG-055009 and ALG-097558 versus the company’s stated 2023 plans, and the quality and completeness of any interim data.
- Progress and final results from ongoing ALG-000184 and ALG-125755 cohorts, including safety, durability and whether reported antiviral effects translate into meaningful clinical benefit.
- Merck’s termination scope and the status, remaining economics and research obligations of the collaboration’s other targets.
- Developments in the Janssen dispute, including any rulings, settlement, intellectual-property consequences or change in estimated exposure.
- Future collaboration receipts versus recognized revenue, operating cash burn, remaining investment liquidity, lease obligations and potential equity dilution.